Arkaitz Castañeda, PhD

CONTACT

Lead Sponsor

University of Deusto

Collaborators

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

No

•Stage pTis-T1-T2-T3 pN0-1 M0 (early stage).
•Patients who have completed local treatment \[surgery + radiotherapy (RT)\] undergoing clinical follow-up in outpatient clinics with or without adjuvant hormone therapy treatment.
•Age: ≥18-60 years.
•ECOG Performance status from 0 to 1 (IK ≥80%).
•Body mass index above than 18.5.
•Without excessive alcohol consumption (men \> 21 and women \> 14 units/week).
•No current or previous illness or injury that may prevent participation and training.
•No recent systematic strength training.
•Not taking medications that are known to alter body composition (corticosteroids, metformin...).
•People who carry out some aerobic training will not be excluded (the activity carried out will be recorded weekly).

•Having received adjuvant or neoadjuvant chemotherapy.
•Metastatic carcinoma of the breast.
•Recurrence or second primary breast.
•History of previous cancer except previously treated basal cell carcinoma of the skin.
•Decompensated heart disease, uncontrolled hypertension (TAS\>200 or TAD\>110), heart failure (NYHA II or greater), heart failure or constrictive pericarditis, neutropenia, severe anemia (Hb\<8.0 g/dl), blood count platelets \<50,000 microL.
•Other health problems in which exercise is contraindicated
•Perform regular physical activity (150 min/week of moderate activity or 75 of vigorous activity), measured with the PVS questionnaire.
•Pregnancy.
•Criterion in the opinion of the investigator of inability to adequately understand the involvement and participation in this clinical study.